Successful achievement of extracorporeal circulation requires that blood coagulability be temporarily interrupted during perfusion and afterward restored to normal. Heparin is accepted as the drug of choice in rendering the blood incoagulable, but there are two drugs, protamine and Polybrene (hexadimethrine bromide), available for effective in vivo neutralization of heparin, and controversy exists as to which of these should be used. In an effort to determine which of these heparin antagonists is superior, comparative studies on protamine and Polybrene were carried out to evaluate heparin neutralization, physiological and hematological effects, and such other matters as may be of practical importance.
In the course of these studies an unexpected fact became apparent. The intravenous injection of protamine or Polybrene resulted in a coagulation factor deficiency, persisting long after the temporary anticoagulant effect of the heparin neutralizer had disappeared. It was possible to demonstrate that a striking loss of Factor VIII (antihemophilic globulin) had been induced.
METHODS
Adult mongrel dogs were used throughout the study, and all animals were anesthetized with intravenous Nembutal (pentobarbital), 30 mg per kg. A measured dose of protamine 1 or Polybrene 2 (up to levels of 5 mg per kg) was rapidly injected into the inferior vena cava through a polyethylene catheter in the femoral vein and the tubing immediately flushed with 10 ml of normal saline. All samples were taken in a siliconized syringe from a catheter inserted into the femoral artery with its tip in * Aided by grants from the National Institutes of Health, Bethesda, Md. Abstracts of material included in this article have been previously published (1, 2) . 1 One per cent solution, Lilly. 2 One per cent solution, Abbott.
the aorta. Prior to each sampling the tubing was first cleared of stagnant blood by removal of 10 ml of blood.
In experiments that did not require repeated withdrawal of blood samples, the two drugs were tested 8 weeks apart in the same animal under identical conditions, thereby allowing each animal to serve as its own control. In all other experiments the two were tested simultaneously in different animals.
Pulse and blood pressure recordings were made through a strain gauge connected to a femoral arterial catheter. Respirations were charted by means of a spirometer connected to a cuffed endotracheal tube. Standard limb lead electrocardiograms were taken.
Protamine and Polybrene levels were measured by heparin titrations, which were performed in some experiments by adding 1 ml of blood from the syringe to each of a row of 12 X 75 mm glass tubes in a water bath at 370 C. Each tube contained 0.1 ml of heparin in amounts of 0 to 50 ,ug at increments of 5 ,tg. Each tube was immediately capped with Parafilm and inverted twice to mix the contents. They were observed for clotting at intervals of 1 minute, the endpoint being a clot which remained solid on tipping the tube past horizontal and tapping it gently against the side of the water bath. The neutralization point was taken as the tube with the greatest amount of heparin in which the shortest clotting time occurred.
In other experiments the titrations were done on plasma from blood collected in 0.1 vol of 3.8 per cent sodium citrate. Each tube contained 0.1 ml of heparin in concentrations of 0 to 10 ,ug at increments of 1 ,g plus 0.1 ml of the plasma to be tested. Then 0.1 ml of 0.025 M calcium chloride was added in rapid succession to each tube, they were mixed, and observed for clotting at intervals of one-half minute. Repeated titrations on the same sample over a period of 6 hours gave the same results.
Lee-White clotting times were done by placing 2 ml of blood in each of three 12 X 75 mm Pyrex tubes in the water bath. The endpoint was taken as the time at which the third tube could be tipped past horizontal without displacing the clot.
Platelet counts were performed on 5-ml blood samples collected in a 15 ml polyethylene vial containing 0.2 ml of 10 per cent disodium ethylenediamine tetraacetic acid (EDTA). The Brecher-Cronkite phase technique was used (3) .
Plasma prothrombin times were determined on blood collected in 0.1 vol 3.8 per cent sodium citrate by the methods of Quick (4) and of Ware and Stragnell (5) . True prothrombin assays were done by a one-stage technique (6) . Prothrombin times on serum were determined after incubation of a 2 ml clot in a 12 X 75 mm Pyrex tube for 1 hour at 370 C. Consumption of prothrombin was stopped at that point by adding 0.9 ml of serum to 0.1 ml 3.8 per cent sodium citrate. The technique of Ware and Stragnell was used.
Cephalin times were done on citrated plasma by adding 0.1 ml optimal dilution of cephalin, prepared by the technique of Bell and Alton (7), and 0.1 ml of 0.025 M calcium chloride to 0.1 ml plasma. The plasma was glassactivated by incubating 0.1 ml in a new 12 X 75 mm Pyrex tube for 3 minutes at 370 C before performing the test.
Fibrinogen levels were measured in the EDTA plasma by the technique of Ratnoff and Menzie (8) . Thromboplastin screening tests were done by the technique of Hicks and Pitney (9), using the Bell and Alton cephalin. Thromboplastin generation tests were done by the technique of Biggs and Macfarlane (10) . Cephalin at optimal dilution was used as a platelet substitute except for experiments where the platelets themselves were being tested. Dilutions of the serum and the absorbed plasma reagents were made as outlined in the Results section.
Factor V levels were assayed by the technique of Borchgrevink, Pool and Stormorken (11) and also with the use of aged oxalate plasma as substrate (12) . In this and all other clotting factor assays, the values are reported as percentage activity related to the control value before the experiment began.
Factor VIII (antihemophilic globulin) was assayed by the technique of Bergna (13) with the following modifications: Serum from clotted whole beef blood was used as a source of Factor IX, Factor X and Factor V. Outdated blood bank plasma from blood collected in acid citrate dextrose solution was used as the substrate on which the amount of plasma thromboplastin generated was assayed. In all assays, appropriate dilutions of plasma were made so that clotting times of the test plasmas would fall in the central part of the curve provided by dilutions of the control plasma (1: 500, 1: 1,000, 1: 2,000, and 1: 4,000). In one experiment, Factor VIII was measured by the cephalin time technique of Langdell, Wagner and Brinkhous (14) using plasma from a proven classical hemophiliac as substrate.
RESULTS
Physiological effect. Table I presents the changes in blood pressure caused by the two drugs at doses of 3 and 5 mg per kg, both with and without prior heparinization. Analysis of these data reveals that the rapid injection of either drug induces a profound hypotension, that the reduced blood pressure persists for several minutes, and that the degree of shock is not influenced by the presence or absence of heparin. Although these effects were more severe and more consistent with protamine than with Polybrene, the differences were small and not statistically significant.
The character of the changes in blood pressure was the same with both drugs. Alterations in pulse were also identical. There was a brief tachycardia followed by a protracted bradycardia. Electrocardiographic tracings in these animals revealed no conduction abnormality with either drug.
Both drugs were capable of producing a pronounced slowing in respiration, at times amounting to apnea (Figure 1 ), followed by prolonged tachypnea. Again these changes were slightly spite the fact that addition of 0.1 vol of undiluted (1 per cent) Polybrene or protamine in vitro to blood could not prolong its clotting time to that extent. This was the first clue that these heparin neutralizers were doing more to the blood coagulation system than could be explained by their known weak anticoagulant effect. There was no significant difference between the two heparin antagonists in these results. Platelet counts showed that both drugs caused an immediate profound thrombocytopenic effect with a slow return to normal levels ( Figure 4 ). There was no significant difference between the two. Fibrinogen levels were variably reduced to a minor degree.
Plasma prothrombin times (Quick and WareStragnell) were prolonged to an insignificant degree by both substances. True prothrombin assays showed no change. Serum prothrombin times ( Figure 5) hibited immediately after injection, and was still abnormal 60 minutes later, long after the platelet count had returned above levels at which it could be responsible for the results. Although the difference was not statistically significant, as shown by the standard deviations in the figure, the effect of Polybrene appeared to be greater than that of protamine.
Cephalin times (Figure 6 ) also showed a marked abnormality, and were not back to the control levels by the end of an hour. Again Polybrene showed the greatest effect although the differences do not appear to be statistically significant. The changes in clotting time, prothrombin consumption, and cephalin times were greater and more persistent than could possibly be explained by the anticoagulant effect of circulating protamine or Polybrene. Proof that the abnormality was due to a clotting factor deficiency rather than to a circulating anticoagulant is provided in Figure  7 , which shows the cephalin times obtained when control plasma was mixed in varying proportions with samples obtained 2, 10 and 60 minutes after Polybrene. In the 2-minute sample, when the Polybrene level was at its highest, a slight anticoagulant effect is apparent in that 10 per cent of the 2-minute plasma prolonged the cephalin time of the control plasma, but even with the 2-minute sample, 10 per cent of control plasma had a significant shortening effect. The ability of a small amount of normal plasma to correct the abnormal plasma (characteristic of a clotting factor deficiency) is clearly apparent with the 10-and 60-minute samples.
The abnormal results with whole blood clotting times, cephalin times, and prothrombin consumptions (compared with the normal prothrombin CEPHALIN (Figure 8) .
It was unlikely that the defect in absorbed plasma was due to a Factor V deficiency, since this would have prolonged the prothrombin times. Specific assays for Factor V showed the rather unexpected result that Factor V levels were actually increased by Polybrene (Table III) .
By exclusion we were thus left with a Factor VIII deficiency as the explanation of our abnormal clotting tests. Direct assays for Factor VIII by a very sensitive technique proved that this was indeed true, and the specificity of the results was corroborated by an assay using plasma from a patient with classical hemophilia as the substrate. The severe depression of antihemophilic globulin levels and the prolonged duration of the defect are very striking (Table IV, line 1). Control levels of Factor VIII in the dogs used were more than five times as high as the average of our normal humans. This explains why the antihemophilic globulin defect became apparent in the TGT only in systems using highly diluted plasmas.
A slower infusion of the same dose of Polybrene (Table IV, line 2) resulted in a slower, milder depression of Factor VIII levels with return toward normal beginning by the end of 1 hour. A second rapid injection given 1 hour after the first (Table IV, line 3), resulted in no further fall in Factor VIII levels despite the fact that simultaneous assays of Polybrene levels showed them to be much higher than those after the first injection (Table II could be used to neutralize heparin in vivo (15) has led to a number of studies to compare its effects with those of the earlier used heparin antagonist, protamine (16) (17) (18) . In two of these studies, it was concluded that Polybrene is to be preferred because, following its use, less postoperative blood loss was noted. These studies discounted (perhaps erroneously) the possibility that the lesser degree of postoperative bleeding might be due to improved techniques of patient management and did not consider the possibility that the dose of Polybrene selected may have come closer to exact neutralization of heparin than did the dose of protamine previously used. One criticism of protamine (16) was that it was unstable and varied in potency. The references quoted in support of this idea were to preparations of protamine available a number of years ago, and this objection is no longer valid according to our experience.
Since early work with Polybrene demonstrated that it could produce the same side effects as protamine ( 15), we performed a series of experiments on dogs in which the magnitude of the effects of the two heparin antagonists could be compared with some exactness. Because protamine clearly had been shown to have an anticoagulant effect in vitro (19, 20) , we were particularly interested in finding out whether this was demonstrable after in vivo injection and whether the findings would be similar with Polybrene.
The results reported above show that there is a marked variability in the responses of individual dogs. Nonetheless, it is apparent that in comparable doses protamine and Polybrene show the same tendency to produce marked hypotension, tachycardia followed by bradycardia, and slowing of respiration followed by tachypnea. Similarly, both drugs demonstrated an equal tendency to induce thrombocytopenia and an unexpected defect of the plasma coagulation system. Although studies demonstrated that Polybrene was a more powerful heparin-neutralizing agent than protamine, it also had a slightly more depressing effect on the blood clotting system.
Polybrene was demonstrated to disappear from the circulating blood very rapidly, as previously had been shown for protamine (21) . The mechanism by which they disappear is unknown but their site of uptake appears to have a limited capacity in view of the much higher blood levels achieved 'When a second injection followed the first. The coagulation defect induced by both drugs persisted long after the heparin antagonists had left the blood stream, and could not be entirely explained by their anticoagulant effect nor by the induced thrombocytopenia. The prolonged whole blood clotting and cephalin times and the poor prothrombin consumption, as compared with normal plasma prothrombin times, suggested that a defect had been induced in the first stage of blood coagulation. Although standard thromboplastin generation and screening tests failed to establish this, more sensitive tests clearly demonstrated that a striking deficiency of Factor VIII had been induced. The animals bled persistently at the site of vessel cannulation, and it thus appears that a temporary coagulation defect had been induced analogous to classical hemophilia.
The mechanism by which Factor VIII is removed from the circulating blood is unclear. The magnitude and duration of the decrease in Factor VIII levels is related to the dose of Polybrene given and the speed at which it is injected. This suggests that the depression of Factor VIII depends on the blood level of Polybrene achieved and that the two may form a complex which is then removed from the circulation. Evidence against this supposition, however, is provided by the fact that a second injection of Polybrene, given while Factor VIII was still at a very low level, did not succeed in reducing the concentration of the coagulation factor further, even though much higher levels of Polybrene appeared in the circulating blood than those following the first dose.
Further objection to the hypothesis of direct interaction between Polybrene and Factor VIII comes from the fact that such a reaction cannot be demonstrated in the test tube. Protamine inhibits thromboplastin generation in vitro but it has not been possible to demonstrate that it acts by opposing Factor VIII. In fact, Shanberge (20) believes it may react with Factor IX. His evidence for this was that serum containing Factor IX appeared to promote thromboplastin generation in the presence of protamine. Shanberge's evidence does not prove direct interaction between protamine and Factor IX; moreover, Hougie (19) was unable to confirm Shanberge's claim that serum had a specific antagonistic action against protamine in the TGT. In any case, no evidence cani be offered to show that protamine and Factor VIII react with each other in vitro. One could speculate that a protamine-or Polybrene-Factor VIII complex does form, that in vivo it is cleared from the circulation, but that in vitro it remains available for products of beginning coagulation to attract Factor VIII and thus disrupt the complex The best argument against the direct interaction between Polybrene and Factor VIII remains the failure of a second dose of Polybrene to lower the Factor VIII levels further.
A second possible explanation for the disappearance of Factor VIII is that it is consumed by beginning intravascular coagulation. This possibility gains weight when we consider the fact that the whole blood clotting times momentarily shortened before they became prolonged, that prior injection of heparin prevented the loss of Factor VIII and that the platelet count fell. On the other hand, intravascular coagulation should consume Factor V, prothrombin and fibrinogen, but these did not decrease. Moreover, thrombocytopenia occurs even with prior heparin. One might speculate that the process of intravascular coagulation was interrupted by the anticoagulant action of Polybrene at some point between the consumption of Factor VIII and that of the other factors mentioned or that just enough thrombin evolved to We hasten to add that we do believe it important that all traces of unneutralized heparin be eliminated in these cases (23) .
Since protamine or Polybrene in appropriate doses can neutralize heparin equally well, and since they demonstrate the same undesirable side effects to approximately the same degree, there is little reason to prefer one to the other. It would seem, therefore, that the choice of drug is less important than the choice of dosage, particularly in regard to avoiding the production of a paradoxical prolongation of clotting by either agent.
SUM MARY
Two heparin antagonists, protamine and Polybrene, have been compared in a series of parallel experiments in vivo and in vitro. The effects of both drugs on blood pressure, pulse, respiration, platelet counts, and blood coagulation are so similar that there is little reason to prefer one over the other. Polybrene neutralizes more heparin than a comparable dose of protamine, but the degree of undesirable side effects appears to correlate with heparin-neutralizing ability.
Large doses of either drug have the unexpected capacity of inducing a striking deficiency of Factor VIII in dogs. Factor V levels are, in contrast, elevated. The mechanism by which these effects are produced is not clear, but it seems probable that the reaction is a nonspecific one and unrelated to the well known anticoagulant effects of these heparin antagonists. It is likely that a similar antihemophilic globulin deficiency may be induced in human patients by the use of excessive doses of heparin antagonists following open heart surgery. The dangers of this situation are obvious, and a plea is made for judicious use of the heparin antagonists.
